

VOID SHEET

TO: License Fee Management Branch

FROM: RTH (RL)

SUBJECT: VOIDED APPLICATION

Control Number: 311474

Applicant: Monsanto Company

Date Voided: 3/5/03

Reason for Void: New license "as proposed" cannot be approved. Licensure "Shared Facilities" of Pharmacia (24-00113-03) - can't authorize.

[Signature]

[Signature] 3/5/03
Signature Date

Attachment:
Official Record Copy of
Voided Action

FOR LFMB USE ONLY

Final Review of VOID Completed:

- Refund Authorized and processed
- No Refund Due
- Fee Exempt or Fee Not Required

Comments: _____

Log completed
Processed by: _____



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

MAR 10 2003

Joseph Eades
Radiation Safety Officer
Monsanto Company
Mail Zone R3B
800 North Lindbergh Blvd.
St. Louis, MO 63167

Dear Mr. Eades:

This refers to your application dated December 18, 2002 requesting a new NRC Type B broad scope license. Based on my preliminary review of your new license application, which included provisions to use byproduct materials possessed under your "new license" at facilities shared with the Pharmacia Corporation, we cannot continue the review for licensed activities as proposed in your application. As we discussed, the terms and conditions of a specific license apply to those locations identified on the license. Only one license can govern activities at a location of use in order to assure security and accountability for the material and use. Consequently, we cannot authorize your proposal to use byproduct material at facilities shared with the Pharmacia Corporation. We have voided your December 18, 2002 request for a new license and are returning the original documents you provided in support of the new license. The new license fees will be refunded to you as well.

In order for Monsanto to pursue the new broad scope Type B license, it will be necessary for you to provide more information regarding the "spin-off" of Monsanto from Pharmacia as an independent organization with no further Pharmacia affiliation. In addition, it will be necessary for you to **specifically identify** those areas of use on the "campus" of Pharmacia that will be covered under the terms and conditions of the Monsanto license. Your new license application should be submitted concurrent to an amendment request from Pharmacia to separate licensed activities between specifically identified Monsanto and Pharmacia facilities. Be advised that you will need to demonstrate your method of controlling access and securing the facilities and materials that will be covered under your license. In addition, if laboratory facilities within buildings on the Pharmacia "campus" will be divided either by building, floor or wing and included on the license that will be issued to the Monsanto Company, you will need to evaluate and provide your procedures for evaluating disposals authorized under 10 CFR Part 20, Section 20.2003. Our concern is that liquid waste generated under two separate licenses will be consolidated into one sanitary sewer system which creates a potential for exceeding the release limits authorized by the regulation. Please address this issue in your waste disposal procedures.

In addition to the above issues, we also discussed your operational history under a broad scope Type B license as well as your experience managing and implementing such a program. Please include a discussion of this information in support of your request for a new Type B broad scope license. When preparing your response to this item, please refer to the "Purpose of Report" (Section 1) of the enclosed copy of NUREG-1556, Volume 11 "Program Specific Guidance About Licenses of Broad Scope" for a discussion regarding broad scope licenses. In addition, you should refer to this document when preparing your application.

In your response, please indicate that the resubmission is additional information to voided Control Number 311474. If you have any questions or require clarification on any of the information stated above, please contact me at (630) 829-9868.

Sincerely,

A handwritten signature in black ink, appearing to read "Patricia J. Pelke". The signature is fluid and cursive, with the first name being the most prominent.

Patricia J. Pelke
Materials Licensing Branch

Enclosures: NUREG-1556, VOLUME 11
Application dated 12/18/02 (with attachments)